The impact of neutralizing antibodies on the risk of disease worsening in interferon β–treated relapsing multiple sclerosis: a 5 year post-marketing study-Reference-Cited by-同舟云学术

The impact of neutralizing antibodies on the risk of disease worsening in interferon β–treated relapsing multiple sclerosis: a 5 year post-marketing study

Published:2013-02-17 Issue:6 Volume:260 Page:1562-1568
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Paolicelli D.,D’Onghia M.,Pellegrini F.,Direnzo V.,Iaffaldano P.,Lavolpe V.,Trojano M.

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

http://link.springer.com/content/pdf/10.1007/s00415-012-6829-3.pdf

Reference40 articles.

1. The IFNB Multiple Sclerosis Study Group I (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661

2. The Multiple Sclerosis Collaborative Research Group (MSCRG) (1996) Intramuscolar interferon beta 1-a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285–294

3. PRISMS Study Group (1998) Randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Lancet 352:1498–1504

4. Bermel RA, Weinstock-Guttman B, Bourdette D et al (2010) Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Mult Scler 16(5):588–596

5. Kappos L, Traboulsee A, Constantinescu C et al (2006) Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 67:944–953

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimization of a Quantitative Anti-Drug Antibodies against Infliximab Assay with the Liquid Chromatography-Tandem Mass Spectrometry: A Method Validation Study and Future Perspectives;Pharmaceutics;2023-05-12

2. Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis;CNS Drugs;2022-05-19

3. Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-β;Multiple Sclerosis and Related Disorders;2020-04

4. Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland;Neurology International;2019-11-29

5. Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle;Journal of Translational Autoimmunity;2019-04